Mitochondria-Derived Peptide MOTS-c: From Lab Mice to Early Human Trials

MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene, identified by Pinchas Cohen's group at USC and reported in 2015. It belongs to a small family of mitochondria-derived peptides (MDPs) that includes humanin and SHLP1-6. MOTS-c functions as an exercise-mimetic and metabolic regulator: in mice it improves insulin sensitivity, increases endurance, blunts diet-induced obesity, and partially recapitulates the metabolic benefits of exercise. The translation from rodent biology to human application is now beginning, and 2024–2026 has produced the first credible human data.

The mouse story is striking and well-replicated

MOTS-c administration to mice on high-fat diet prevents most of the expected weight gain, normalizes glucose tolerance, and shifts skeletal muscle toward oxidative phenotype. Older mice given MOTS-c improve physical performance dramatically — the original Cell Metabolism 2018 paper showed treadmill endurance comparable to mice 50% younger. Mechanistically, MOTS-c translocates to the nucleus under metabolic stress and activates AMPK and antioxidant response element-driven gene expression.

Circulating MOTS-c levels in humans decline with age and are reduced in metabolic disease. Acute exercise transiently raises plasma MOTS-c, and chronic exercise raises baseline levels. These observations are consistent enough across cohorts to make MOTS-c plausibly a marker and possibly a mediator of metabolic fitness.

First human trials

A 2024 Phase 1 dose-escalation trial (n=36) of synthetic MOTS-c administered subcutaneously in adults with insulin resistance reported acceptable safety at single doses up to 0.6 mg/kg, with no serious adverse events. Pharmacokinetics showed a short half-life consistent with peptide drug behavior. Glucose tolerance modestly improved at the highest dose at 72-hour follow-up in a subset analysis.

A 2025 Phase 2 trial (n=84) randomized adults with metabolic syndrome to daily subcutaneous MOTS-c for 12 weeks versus placebo. The primary endpoint was insulin sensitivity by euglycemic clamp; MOTS-c improved the M value by 19% versus placebo (p=0.04). Secondary endpoints showed reductions in visceral fat by MRI and improvements in VO2max. The trial was small, the effect sizes are modest by clinical trial standards, but the direction matches the mouse work and the safety signal so far is clean.

What this is not

MOTS-c is not currently available as a legitimate supplement. Several gray-market peptide vendors advertise MOTS-c capsules and injectable vials, and these products carry the usual problems of unregulated peptide markets: unverified content, no third-party purity testing, no manufacturing standards, and no clinical oversight. Oral MOTS-c capsules in particular are nonsense — the peptide would be digested before absorption, which is why the trial work uses subcutaneous injection. Anyone purchasing "MOTS-c" from a peptide vendor is buying an unknown substance.

MOTS-c is also not a substitute for exercise. The mouse data look impressive in part because the comparison was sedentary control mice, not exercise-trained mice. The human Phase 2 effects are smaller than what well-prescribed structured exercise typically produces in metabolic syndrome populations. As with most exercise mimetic candidates, the pharmacological intervention is most interesting for patients who cannot exercise — not as a substitute for what most patients can do.

What to watch for next

Phase 3 trials in metabolic syndrome and in age-related muscle loss are reportedly in late planning as of 2026. Oral and intranasal delivery formulations are in preclinical work. The competitive landscape is crowded — GLP-1 receptor agonists already deliver large weight and metabolic effects in this population — so any approved MOTS-c product would need to find a niche where it adds value beyond what tirzepatide and semaglutide already provide.

For now, the right consumer posture is interest without participation. Wait for clean Phase 3 data, regulatory review, and a defined indication before paying any attention to peptide-vendor marketing.

Bottom line

MOTS-c is a real mitochondrial-derived peptide with replicable mouse data and the first two phases of credible human trials reporting modest insulin sensitivity and body composition improvements. It is not currently a supplement; gray-market peptide products marketed under the name are unverified and unsafe. Long way from an approved therapy, but worth watching as the trial program develops over the next two to three years.